We ran a flow cytometry experiment where Fc blockers were added into the antibody cocktail. Other antibodies added include:
1. anti-CD3-PE-Cy7
2. anti-CD4-APC
3. anti-CD8-AmCyan
4. anti-CD14-APC-Cy7
5. anti-CD19-BV605
6. anti-pSTAT1-AF488
7. anti-pTAT3-PE
8. anti-pSTAT5-BV421
Before Fc blockers were added, the monocyte population expressed high levels of CD3. We speculated that the anti-CD3 antibody might undergo non-specific binding to FcR. However, adding Fc blockers did not change the CD3 expression.
Is there any possible scenario of why this happened?